Страна: Ізраїль
мова: англійська
Джерело: Ministry of Health
RIVAROXABAN
TARO PHARMACEUTICAL INDUSTRIES LTD
B01AX06
FILM COATED TABLETS
RIVAROXABAN 10 MG
PER OS
Required
TARO PHARMACEUTICAL INDUSTRIES LTD
RIVAROXABAN
* Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.* Prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE), in adults (following completion of at least 6 months therapy for DVT or PE).
2019-08-06
_Page 1 of 8 _ Patient leaflet in accordance with the Pharmacists’ Regulations (Preparations) - 1986 This medicine is dispensed with a doctor's prescription only Rivaroxaban Taro 10 mg Film-coated tablets Active ingredient Each tablet contains: rivaroxaban 10 mg Inactive ingredients and allergens in the medicine: see section 2 under ‘Important information about some of this medicine’s ingredients’, and section 6 ‘Additional information'. Read the entire leaflet carefully before you start using this medicine. This leaflet contains concise information about this medicine. If you have any further questions, consult your doctor or pharmacist. This medicine has been prescribed to treat your illness. Do not pass it on to others. It may harm them, even if it seems to you that their illness is similar to yours. In addition to the leaflet, Rivaroxaban Taro also has a patient safety information card. This card contains important safety information that you need to know and that you should follow before you start and during treatment with Rivaroxaban Taro. Carefully read the patient safety information card and patient information leaflet before using this medicine. Keep the card and the leaflet in case you need to read it again. 1. What is this medicine intended for? Rivaroxaban Taro 10 mg is intended for: • Prevention of the development of blood clots in the veins in adults after an elective hip or knee replacement operation. • Prevention of re-ocurrence of blood clots in leg veins (deep vein thrombosis, DVT) and in the blood vessels of the lungs (pulmonary embolism, PE), after completing 6 months of treatment for deep vein thrombosis or previous pulmonary embolism. Therapeutic group: rivaroxaban belongs to a group of medicines called antithrombotic agents and works by blocking a blood clotting factor (factor Xa) and thus reducing the tendency of the blood to form clots. 2. Before using this medicine Do not use this medicine if: _Page 2 of 8 _ • you are sensitive (allergic) to rivaroxaban or to any of the o Прочитайте повний документ